Main Logo
SOHO 2024: Focus on AML
Sorafenib Demonstrates Survival Benefit in AML, More Safety Data Needed
Rebecca AraujoAcute Myeloid Leukemia | September 18, 2024
Sorafenib, a FLT3 inhibitor, led to significantly improved survival compared with placebo in patients with AML.
Read More

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    Formedics logo© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |